Invesco’s Dicerna Pharmaceuticals DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-430,348
| Closed | -$8.68M | – | 4145 |
|
|
2021
Q3 | $8.68M | Buy |
430,348
+240,293
| +126% | +$6.63M | ﹤0.01% | 2080 |
|
|
2021
Q2 | $7.09M | Sell |
190,055
-100,830
| -35% | -$3.09M | ﹤0.01% | 2261 |
|
|
2021
Q1 | $7.44M | Sell |
290,885
-4,849
| -2% | -$124K | ﹤0.01% | 2143 |
|
|
2020
Q4 | $6.52M | Sell |
295,734
-55,078
| -16% | -$1.21M | ﹤0.01% | 2050 |
|
|
2020
Q3 | $6.31M | Sell |
350,812
-13,542
| -4% | -$280K | ﹤0.01% | 1889 |
|
|
2020
Q2 | $9.26M | Sell |
364,354
-121,871
| -25% | -$2.63M | ﹤0.01% | 1672 |
|
|
2020
Q1 | $8.93M | Buy |
486,225
+443,858
| +1,048% | +$8.63M | ﹤0.01% | 1587 |
|
|
2019
Q4 | $934K | Buy |
+42,367
| New | +$853K | ﹤0.01% | 3029 |
|
|
2019
Q1 | – | Sell |
-141,438
| Closed | -$1.51M | – | 3881 |
|
|
2018
Q4 | $1.51M | Buy |
+141,438
| New | +$1.86M | ﹤0.01% | 2732 |
|
|
2015
Q3 | – | Sell |
-368
| Closed | -$5K | – | 4089 |
|
|
2015
Q2 | $5K | Sell |
368
-62,571
| -99% | -$1.15M | ﹤0.01% | 4241 |
|
|
2015
Q1 | $1.51M | Buy |
+62,939
| New | +$1.42M | ﹤0.01% | 2796 |
|
Other funds holding DRNA
Invesco's DRNA Position: Q4 2021 in Review
Invesco sold out of Dicerna Pharmaceuticals (DRNA) in Q4 2021, closing a stake of 430,348 shares — an estimated $8.68M sold.
Invesco first reported a position in DRNA in Q1 2015 and held it in 11 quarters. The position peaked at $9.26M in Q2 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Invesco reported no remaining Dicerna Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Invesco sold 430,348 Dicerna Pharmaceuticals shares in Q4 2021, an estimated $8.68M.
- Invesco first reported a position in Dicerna Pharmaceuticals in Q1 2015 and held it in 11 quarters.
- Invesco's Dicerna Pharmaceuticals position peaked at $9.26M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals as of Q4 2021.
Based on Invesco's 13F filing for Q4 2021, filed 14 Feb 2022.